Cefepime Safety in Pregnancy
Cefepime can be used during pregnancy when clinically indicated, though data are limited; standard adult dosing (1-2g IV every 8-12 hours depending on infection severity) is appropriate for pregnant women with normal renal function, as no specific dose adjustments are recommended based solely on pregnancy status.
Safety Profile
Cefepime belongs to the fourth-generation cephalosporins, and while specific pregnancy safety data for cefepime are sparse, the broader cephalosporin class has an established safety record in pregnancy. The 2020 European Respiratory Society guidelines classify ceftazidime (a related third-generation cephalosporin) as pregnancy category B1/B, noting that "most studies found that cephalosporin antibiotics in general are safe to use in pregnancy" with no fetal damage in animal studies 1. This class effect provides reassurance for cefepime use when needed.
Recent pharmacokinetic modeling confirms that cefepime can be used throughout pregnancy, though physiological changes during the second and third trimesters may affect drug exposure 2, 3. Specifically, pregnant women experience increased volume of distribution (9.2-18.4%) and increased clearance (30.8-100%) compared to non-pregnant women 3. However, the FDA label does not specify pregnancy-specific dose adjustments 4.
Dosing Recommendations
Standard Adult Dosing (Normal Renal Function)
For pregnant adults with creatinine clearance >60 mL/min, use standard dosing based on infection severity 4:
- Mild-moderate UTI/pyelonephritis: 0.5-1g IV every 12 hours
- Severe UTI: 2g IV every 12 hours
- Moderate-severe pneumonia: 1-2g IV every 8-12 hours
- Pseudomonas infections: 2g IV every 8 hours
- Complicated intra-abdominal infections (with metronidazole): 2g IV every 8-12 hours
- Febrile neutropenia: 2g IV every 8 hours
Administer each dose intravenously over approximately 30 minutes 4.
Renal Impairment Adjustments
If the pregnant patient has renal impairment (CrCl ≤60 mL/min), dose reduction is mandatory 4:
- CrCl 30-60: Reduce frequency to every 24 hours (or every 12 hours for severe infections requiring 2g q8h)
- CrCl 11-29: Further reduce to 250-500mg or 1-2g every 24 hours depending on indication
- CrCl <11: 250mg-1g every 24 hours depending on severity
Clinical Considerations
Physiological Changes in Pregnancy
The increased clearance during pregnancy theoretically could reduce drug exposure and target attainment, particularly in the third trimester 3. While evidence-based dosing adjustments have been proposed for some cephalosporins (cefazolin, cefuroxime, ceftazidime), specific pregnancy dosing recommendations for cefepime are not yet established 3. In clinical practice, this means:
- Monitor clinical response closely
- Consider therapeutic drug monitoring in severe infections if available
- For serious Pseudomonas infections, ensure the higher dose (2g every 8 hours) is used
Common Pitfalls to Avoid
- Don't underdose severe infections: The physiological changes of pregnancy may reduce drug levels; use the upper end of dosing ranges for serious infections
- Don't forget renal function assessment: Pregnancy can affect renal function; calculate CrCl and adjust accordingly
- Don't assume all cephalosporins are identical: While the class is generally safe, individual agents have varying data quality
- Don't continue unnecessarily: Use the shortest effective duration (typically 7-10 days for most indications) 4
When to Use Cefepime in Pregnancy
Cefepime is appropriate for pregnant women with:
- Serious gram-negative infections requiring broad-spectrum coverage
- Pseudomonas aeruginosa infections (where it provides superior coverage)
- Febrile neutropenia
- Multidrug-resistant organisms when susceptibility testing supports its use 5
The decision to use cefepime should weigh the severity of maternal infection (which poses direct risks to both mother and fetus) against the theoretical concerns from limited pregnancy-specific data. For serious bacterial infections, the benefits of appropriate antibiotic therapy clearly outweigh potential risks.